Table 1. Patients' characteristics (total 250 who were enrolled).
| Group A (n=168) | Group B (n=82) | P value | |
|---|---|---|---|
| Hospital location | 55 (32.7) | 24 (29.3) | |
| Beijing, n (%) | 26 (15.5) | 12 (14.6) | |
| Shanghai, (n (%) | 20 (11.9) | 10 (12.2) | |
| Changsha, n (%) | 35 (20.8) | 16 (19.5) | |
| Wuhan, n (%) | 32 (19.1) | 20 (24.4) | |
| Guangzhou, n (%) | |||
| Age (years) | 61.7±5.3 | 60.8±5.9 | 0.315 |
| Body mass index (kg m−2) | 23.5±3.9 | 24.0±3.5 | 0.441 |
| Qmax (ml s−1) | 10.7±2.1 | 11.2±1.3 | 0.074 |
| PVR (ml) | 23.0±14.1 | 20.5±11.3 | 0.181 |
| BPH/LUTS severity | |||
| Moderate (IPSS 10–19), n (%) | 102 (60.8) | 54 (65.8) | 0.431 |
| Severe (IPSS ≥20), n (%) | 66 (39.2) | 28 (34.2) | |
| ED severity | |||
| Mild (IIEF-5 17-21), n (%) | 13 (7.7) | 8 (9.7) | 0.535 |
| Moderate (IIEF-5 12–16), n (%) | 126 (75.0) | 56 (68.3) | |
| Severe (IIEF-5 5-11), n (%) | 29 (17.3) | 18 (22.0) |
Abbreviations: BPH/LUTS, lower urinary tract symptoms secondary to benign prostatic hyperplasia; ED, erectile dysfunction; IIEF-5, International Index of Erection Function-5; IPSS, International Prostate Symptom Score; PVR, post-void residual; Qmax, a maximum urinary flow rate.
Group A, sildenafil and doxazosin GITS combined therapy. Group B, sildenafil monotherapy. Values are expressed as mean±s.d. unless stated otherwise. Independent and paired t-test was carried out for the agents of age, body mass index, Qmax and PVR. Chi-square test was carried out for the agent of ED and BPH/LUTS severity.